GlassScriptPhysician profile
Eric Yoon
NPI 1750624532
$23,296.51
in general payments reported to CMS, 2019-2025
50 companies · $5,413 in 2025
The $5,413 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $460 · 2021: $2,137 · 2022: $3,883 · 2023: $5,419 · 2024: $5,594 · 2025: $5,413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Travel and Lodging: $965 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,438.47 |
| Travel and Lodging | $965.08 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,244.02 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Abbvie INC. | $4,891.96 | 2019-2025 | Linzess, Skyrizi, Creon |
| Qol Medical, LLC | $1,505.48 | 2020-2025 | Sucraid, Sucraid |
| Stryker Corporation | $1,423.54 | 2021-2025 | Infinity, Alphavent, Mako |
| Janssen Biotech, INC. | $1,052.76 | 2019-2025 | Tremfya, Stelara |
| Skeletal Dynamics INC | $1,051.62 | 2024-2025 | Implate, Align, Ijs |
| Ardelyx, INC. | $908.32 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $837.06 | 2020-2025 | Entyvio |
| Phathom Pharmaceuticals, INC. | $721.07 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $555.10 | 2020-2025 | Talicia, Movantik, Aemcolo |
| Regeneron Healthcare Solutions, INC. | $554.16 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $542.84 | 2021-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $525.54 | 2021-2024 | Zeposia |
| Pfizer INC. | $507.72 | 2024-2025 | |
| Genzyme Corporation | $474.54 | 2023-2024 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.